Despite advances in neurosurgical techniques and radio-/chemotherapy, the treatment of brain tumors remains a challenge. This is particularly true for the most frequent and fatal adult brain tumor, glioblastoma (GB). Upon diagnosis, the average survival time of GB patients remains only approximately 15 months. The alkylating drug temozolomide (TMZ) is routinely used in brain tumor patients and induces apoptosis, autophagy and unfolded protein response (UPR). Here, we review these cellular mechanisms and their contributions to TMZ chemoresistance in brain tumors, with a particular emphasis on TMZ chemoresistance in glioma stem cells and GB.

中文翻译：

---

胶质母细胞瘤和对烷化剂的化学耐药性：涉及细胞凋亡，自噬和未折叠的蛋白质反应

尽管在神经外科技术和放射/化学疗法方面取得了进步，但是脑肿瘤的治疗仍然是一个挑战。对于最常见和致命的成年脑肿瘤胶质母细胞瘤（GB）尤其如此。经诊断，GB患者的平均生存时间仅约15个月。烷基化药物替莫唑胺（TMZ）通常用于脑肿瘤患者，并诱导凋亡，自噬和未折叠蛋白反应（UPR）。在这里，我们审查这些细胞机制及其在脑肿瘤中对TMZ耐药的贡献，特别着重于神经胶质瘤干细胞和GB中的TMZ耐药。